Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Returns Brinavess Rights To Cardiome | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merck Returns Brinavess Rights To Cardiome

Plans continued advancement of AF drug in North America

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck will return the global marketing and development rights for intravenous (IV) and oral formulations for vernakalant to Cardiome Pharma. The company referred to the move as “a business decision.”
 
Vernakalant IV is marketed under the brand name Brinavess and is approved in the EU for recent onset atrial fibrillation (AF) to sinus rhythm in adults. Vernakalant IV is not approved for use in the U.S. or Canada. The companies will work together to transition activities and ensure continued availability of the product.
 
“Cardiome looks forward to continued advancement of the launch of Brinavess IV worldwide and welcomes the opportunity to continue development of vernakalant oral worldwide and vernakalant IV in North America,” said Dr. William Hunter, interim chief executive officer of Cardiome. “We thank Merck for its contribution to the Vernakalant program and anticipate a smooth transition for the physicians and patients who rely on Brinavess.”
 
Michael Mendelsohn, M.D., senior vice president and head, atherosclerosis and cardiovascular research, Merck Research Laboratories, said, “We continue to support the safety and efficacy profile of vernakalant. We look forward to working with Cardiome to conduct a transition that has the best interests of patients and their physicians in mind. Merck remains committed to developing new drugs for cardiovascular diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters